Compare PAX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | CAPR |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2020 | 2011 |
| Metric | PAX | CAPR |
|---|---|---|
| Price | $11.17 | $19.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $18.00 | ★ $44.63 |
| AVG Volume (30 Days) | 796.0K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.99 | N/A |
| Revenue Next Year | $16.52 | $3.31 |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.56 | $4.30 |
| 52 Week High | $17.80 | $40.37 |
| Indicator | PAX | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 30.67 |
| Support Level | $11.04 | $5.25 |
| Resistance Level | $11.38 | $30.39 |
| Average True Range (ATR) | 0.24 | 1.33 |
| MACD | 0.04 | -0.17 |
| Stochastic Oscillator | 60.75 | 21.68 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.